Alzheimers Disease Drug Market Analysis 2026

Global Alzheimers Disease Drug Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends

Alzheimers Disease Drug Market Report Description

We have various report editions of Alzheimers Disease Drug Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Impact of Tariff Trumph on Pharmaceuticals Industry

The April 2025 “Liberation Day Tariffs” (10–46%) have disrupted global pharmaceutical trade, raising costs for APIs, packaging, and machinery from China and India. Generic drug makers, biopharma, vaccines, and CMOs face higher expenses, supply chain delays, and regulatory hurdles, while EU retaliation has further strained U.S. exports. Clinical trials are also delayed due to tariffs on drugs and kits. In this landscape, market research is vital, providing real-time data on pricing, suppliers, and tariff impacts to help companies optimize supply chains, find alternative hubs, and maintain competitiveness.

Alzheimers Disease Drug Market Insights Video

• Majority of global manufacturers of Alzheimer’s Disease Drug are demonstrating world-class sustainable practices and are attracting a lot of capital. New product launches, pipeline products and R&D activities are some of the key strategies adopted by the key players to acquire a greater market share.
• The report involves complete profiling of below mentioned players which are identified among the top players. Numerous medicines for the symptomatic management of Alzheimer's disease are available in a fragmented market. Numerous suppliers are being forced to create new vaccinations due to the disease's high incidence and the demand for extremely effective therapies.

News

• September 2022

Eisai Co., Ltd. and Biogen Inc. completed the submission of Biologics License Application to U.S. Food and Drug Administration for lecanemab:
Eisai Co., Ltd. and Biogen Inc. announced that it has completed the rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application (BLA) under the accelerated approval pathway for the investigational anti-amyloid beta (Aβ) protofibril antibody lecanemab (BAN2401) for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain.

• July 2021

AbbVie plans to move next-gen Aduhelm hopeful for Alzheimer's into the clinic
AbbVie has planned to push an Alzheimer’s disease candidate that potentially has a better safety profile into the clinic by year’s end or early next year. The company is pursuing a range of possible ways to tackle Alzheimer’s. Those include AL002, a monoclonal antibody trying to enhance the activity of the TREM2 gene, and AL003, which targets a genetic link to the disease, called sialic acid binding Ig-like lectin 3 (SIGLEC 3).

• November 2017

Novartis and Amgen have entered into collaboration with Banner Alzheimer's Institute
Novartis, Amgen and the Banner Alzheimer's Institute (BAI) has expanded collaboration in which the companies initiated a new trial - the Alzheimer's Prevention Initiative (API) Generation Study 2. This trial follows the launch of the Generation Study 1, and thus it determined whether the BACE1 inhibitor CNP520 can prevent or delay the onset of Alzheimer's disease symptoms in a high-risk population.

• November 2022

Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer’s disease
Roche announced results from the GRADUATE I and II studies evaluating gantenerumab in people with mild cognitive impairment (MCI) due to Alzheimer’s and mild Alzheimer’s dementia, collectively called early Alzheimer’s disease. Gantenerumab was well tolerated, including the subcutaneous administration.

Top Companies Market Share in Alzheimers Disease Drug Industry: (In no particular order of Rank)

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive)

Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

As per our analysis, market share for Alzheimer’s Disease Drug in North America is over 40%. Hence North America is dominating the market with USD XX Bn in 2021. High number of people in America shows symptoms for Alzheimer’s disease and this number is continuously increasing. Thus, demand for AD drugs is significant in North America. Further, U.S. Food and Drug Administration approved Aduhelm recently for the treatment of Alzheimer’s, a debilitating disease affecting 6.2 million Americans.
Two years of COVID-19 pandemic have shifted the dynamics in the US healthcare value chain. Innovation and growth continued unabated in services. acceleration of value-based care models and increasing application of technology across the healthcare industry are likely to continue in the long term. All these parameters driven North America market for Alzheimer’s Disease Drug.
Asia-Pacific Alzheimer’s Disease Drug market is set to show significant growth rate in coming years
Asia-Pacific Alzheimer’s Disease Drug market is set to display growth at a high compound annual growth rate as countries/territories on multiple metrics, New Zealand, Australia, Hong Kong, and Japan along with China and India has high potential for healthcare sector. Growing population, and increasing awareness has stimulated growth for this market. Further, like U.S., China and Japan are also experiencing growth in its geriatric population.
Alzheimer’s Disease Drug is also seeing a rapid rise in popularity in Europe, partly due to an overall growth in the European geriatric population.

The current report Scope analyzes Alzheimers Disease Drug Market on 6 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe)
• Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East)
• Africa (East Africa, West Africa, North Africa, South Africa)

The above graph is for illustrative purposes only.

Author's Conclusion

Author's Detail

Research Analyst

LinkedIn | Profile | Book Appointment

Supriya Yadav is a dedicated market research professional with expertise in the aerospace and defence industry. At Cognitive Market Research, she focuses on delivering strategic insights into aviation advancements, defence technologies, and global security trends shaping the future of the sector.

Her research covers areas such as military modernization, commercial aviation growth, space exploration, and defence procurement strategies. With a strong analytical mindset and attention to technological evolution, Supriya provides data-driven intelligence that supports innovation, strategic planning, and informed decision-making within the aerospace and defence domain.